Literature DB >> 7986174

Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative.

D Blacker1, M S Albert, S S Bassett, R C Go, L E Harrell, M F Folstein.   

Abstract

OBJECTIVE: To assess interrater reliability and validity of NINCDS-ADRDA (National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association) criteria for Alzheimer's disease (AD).
DESIGN: A multisite reliability and validity study in which clinicians from each site diagnosed 60 case summaries yielding a preconsensus estimate of reliability and validity. A consensus conference was conducted for each disagreement, leading to a postconsensus estimate of validity. The criterion standard was a diagnosis of AD by autopsy.
SETTING: Three academic medical centers.
SUBJECTS: A convenience sample of 60 detailed case summaries, 40 with AD and 20 with other dementing disorders. MAIN OUTCOME MEASURES: The kappa coefficient, sensitivity, and specificity.
RESULTS: The kappa coefficient for preconsensus agreement on a diagnosis of probable or possible AD vs non-AD was 0.51; the sensitivity of a diagnosis of probable or possible AD for a pathological diagnosis of AD was 0.81, and the specificity was 0.73. The postconsensus sensitivity was 0.83, and the specificity was 0.84.
CONCLUSIONS: The results support the reliability and validity of NINCDS-ADRDA criteria and show that the consensus process may improve diagnostic accuracy. The cases are reviewed with a focus on the sources of diagnostic disagreements and errors and possible changes that might improve the accuracy of the criteria.

Entities:  

Mesh:

Year:  1994        PMID: 7986174     DOI: 10.1001/archneur.1994.00540240042014

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  51 in total

1.  A single-photon emission computed tomography imaging study of driving impairment in patients with Alzheimer's disease.

Authors:  B R Ott; W C Heindel; W M Whelihan; M D Caron; A L Piatt; R B Noto
Journal:  Dement Geriatr Cogn Disord       Date:  2000 May-Jun       Impact factor: 2.959

Review 2.  Behavioural problems associated with dementia: the role of newer antipsychotics.

Authors:  G Stoppe; C A Brandt; J H Staedt
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

Review 3.  Evolution of the diagnostic criteria for degenerative and cognitive disorders.

Authors:  Oscar L Lopez; Eric McDade; Mario Riverol; James T Becker
Journal:  Curr Opin Neurol       Date:  2011-12       Impact factor: 5.710

4.  Brain SPET perfusion in early Alzheimer's disease: where to look?

Authors:  Ingeborg Goethals; Christophe Van De Wiele; Daniel Slosman; Rudi Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-08       Impact factor: 9.236

5.  Odorant Item Specific Olfactory Identification Deficit May Differentiate Alzheimer Disease From Aging.

Authors:  Matthew R Woodward; Muhammad Ubaid Hafeez; Qianya Qi; Ahmed Riaz; Ralph H B Benedict; Li Yan; Kinga Szigeti
Journal:  Am J Geriatr Psychiatry       Date:  2018-04-19       Impact factor: 4.105

6.  Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.

Authors:  David A Wolk; Carl Sadowsky; Beth Safirstein; Juha O Rinne; Ranjan Duara; Richard Perry; Marc Agronin; Jose Gamez; Jiong Shi; Adrian Ivanoiu; Lennart Minthon; Zuzana Walker; Steen Hasselbalch; Clive Holmes; Marwan Sabbagh; Marilyn Albert; Adam Fleisher; Paul Loughlin; Eric Triau; Kirk Frey; Peter Høgh; Andrea Bozoki; Roger Bullock; Eric Salmon; Gillian Farrar; Christopher J Buckley; Michelle Zanette; Paul F Sherwin; Andrea Cherubini; Fraser Inglis
Journal:  JAMA Neurol       Date:  2018-09-01       Impact factor: 18.302

7.  Validation of olfactory deficit as a biomarker of Alzheimer disease.

Authors:  Matthew R Woodward; Chaitanya V Amrutkar; Harshit C Shah; Ralph H B Benedict; Sanjanaa Rajakrishnan; Rachelle S Doody; Li Yan; Kinga Szigeti
Journal:  Neurol Clin Pract       Date:  2017-02

8.  TDP-43 frontotemporal lobar degeneration and autoimmune disease.

Authors:  Zachary A Miller; Katherine P Rankin; Neill R Graff-Radford; Leonel T Takada; Virginia E Sturm; Clare M Cleveland; Lindsey A Criswell; Philipp A Jaeger; Trisha Stan; Kristin A Heggeli; Sandy Chan Hsu; Anna Karydas; Baber K Khan; Lea T Grinberg; Maria Luisa Gorno-Tempini; Adam L Boxer; Howard J Rosen; Joel H Kramer; Giovanni Coppola; Daniel H Geschwind; Rosa Rademakers; William W Seeley; Tony Wyss-Coray; Bruce L Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-03-30       Impact factor: 10.154

9.  Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity.

Authors:  Minji Kim; Jaehong Suh; Donna Romano; Mimy H Truong; Kristina Mullin; Basavaraj Hooli; David Norton; Giuseppina Tesco; Kathy Elliott; Steven L Wagner; Robert D Moir; K David Becker; Rudolph E Tanzi
Journal:  Hum Mol Genet       Date:  2009-07-15       Impact factor: 6.150

10.  Accumulation of neutral lipids in peripheral blood mononuclear cells as a distinctive trait of Alzheimer patients and asymptomatic subjects at risk of disease.

Authors:  Alessandra Pani; Antonella Mandas; Giacomo Diaz; Claudia Abete; Pier Luigi Cocco; Fabrizio Angius; Annalisa Brundu; Nico Muçaka; Maria Elena Pais; Antonio Saba; Luigi Barberini; Cristina Zaru; Manuela Palmas; Paolo F Putzu; Alessandra Mocali; Francesco Paoletti; Paolo La Colla; Sandra Dessì
Journal:  BMC Med       Date:  2009-11-02       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.